Efficacy of GLP-1 receptor agonists

Meta-analyses including data from randomised controlled trials assessing clinically relevant doses of GLP-1 receptor agonists administered for longer periods have been published. The results provide evidence that intervention with clinical relevant doses of currently available GLP-1 receptor agonists (exenatide, exenatide once-weekly and liraglutide) facilitate reduction in body weight in obese patients both with and without diabetes. GLP-1 receptor agonists also had beneficial effects on the systolic and diastolic blood pressure and cholesterol. For patients with type 2 diabetes, GLP-1 receptor agonists improved glycaemic control (as assessed by HbA1c and fasting plasma glucose) and increased the proportion of patients who achieved the target HbA1c.


Nobody has commented on this article

Commenting is only available for registered Diapedia users. Please log in or register first.